Long pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting

Basit Öğe Kaydı
dc.authoridTURK, UGUR ONSEL/0000-0001-6348-6616
dc.authoridErcan, Ertugrul/0000-0003-0480-4738
dc.contributor.authorSaygi, Serkan
dc.contributor.authorKirilmaz, Bahadir
dc.contributor.authorTengiz, Istemihan
dc.contributor.authorTurk, Ugur Onsel
dc.contributor.authorYildiz, Hicran
dc.contributor.authorTuzun, Nurullah
dc.contributor.authorAlioglu, Emin
dc.date.accessioned2025-01-27T20:23:12Z
dc.date.available2025-01-27T20:23:12Z
dc.date.issued2012
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjectives: We analyzed pentraxin 3 (PTX3) levels and the relation of PTX3 levels with GRACE risk scores in 39 patients with non-ST elevation acute coronary syndrome (ACS) and stabile angina after stenting. Study design: Seventeen patients with ACS and 22 patients with stabile angina who underwent coronary stenting were included in the study. PTX3 levels were measured serially at admission, at the 8th hour and at the 24th hour after stenting. Results: While diabetes and hypertension were more frequent in the stabile angina group, leukocyte counts were significantly higher in the ACS group. PTX3 levels measured at the 8th hour were significantly higher in the ACS group compared to the stabile angina group (p=0.003). Strong correlations were observed between 24th hour PTX3 levels and GRACE scores calculated for risk of death and death/MI at admission (in-hospital/to 6 months), and for risk of death/MI at discharge to 6 months (R=0.571, p=0.01, R=0.564, p=0.01; R=0.558, p=0.02, R=0.512, p=0.03; R=0.653, p=0.004, respectively). Conclusion: The serum PTX3 levels may provide important information for the early risk stratification of patients with ACS who underwent coronary stenting.
dc.identifier.doi10.5543/tkda.2012.90083
dc.identifier.endpage212
dc.identifier.issn1016-5169
dc.identifier.issue3
dc.identifier.pmid22864315
dc.identifier.scopus2-s2.0-84864198431
dc.identifier.scopusqualityQ3
dc.identifier.startpage205
dc.identifier.trdizinid161797
dc.identifier.urihttps://doi.org/10.5543/tkda.2012.90083
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/161797
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22148
dc.identifier.volume40
dc.identifier.wosWOS:000421817400001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAves
dc.relation.ispartofTurk Kardiyoloji Dernegi Arsivi-Archives of The Turkish Society of Cardiology
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectAcute coronary syndrome
dc.subjectangina pectoris
dc.subjectatherosclerosis C-reactive protein
dc.subjectGRACE risk score
dc.subjectmyocardial infarction
dc.subjectpentraxin
dc.titleLong pentraxin-3 measured at late phase associated with GRACE risk scores in patients with non-ST elevation acute coronary syndrome and coronary stenting
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu